Proyectos de Research Projects
- Novel Advanced Engineering Strategies to Optimize CAR-T Cell Function and Persistence in Multiple Myeloma
Project Title: Novel Advanced Engineering Strategies to Optimize CAR-T Cell Function and Persistence in Multiple Myeloma
(PI22/00647)
Financing agency: Carlos III Health Institute
Start and end date: 01/01/2023 – 31/12/2025
- Analysis of the chromatin accesibility landscape and regulatory networks of igm monoclonal gammopathies: Towards a better understanding of progression mechanisms
Project title: Analysis of the chromatin accesibility landscape and regulatory networks of igm monoclonal gammopathies: Towards a better understanding of progression mechanisms. ( INT_ IWMF_SMI_22)
Funding agency: International Waldenstrom’s Macroglobulinemia Foundation
Start and end date: 26/10/2022 – 25/10/2023
- Immunotherapy for Multiple Myeloma
Project title: Immunotherapy for Multiple Myeloma: A New Generation of Chimeric Antigen Receptors and Immune Checkpoint Blockad (IMS_TRG_22_01)
Funding agency: Sociedad Internacional de Mieloma
Start and end date: 01/03/2022 – 09/08/2023
- Results-Oriented Cooperative Research Networks in Greeting 2021
Project title: Results-Oriented Cooperative Research Networks in Greeting 2021. RICORS TERAV
Financing agency: Carlos III Health Institute
Start and end date: 01/01/2022 – 12/31/2024
- Strategies to overcome antigen escape relapses and improve CAR T-cell persistence in multiple myeloma
Project title: Strategies to overcome antigen escape relapses and improve CAR T-cell persistence in multiple myeloma
(LABAE21971FERN)
Funding agency: Foundation of the Spanish Association against Cancer (AECC)
Start and end date: 01/11/2021 – 31/10/2024
- Optimization of immunotherapy with CAR T cells through the inhibition of immune checkpoints to achieve a prolonged response in patients with multiple myeloma
Project title: Optimization of immunotherapy with CAR T cells through the inhibition of immune checkpoints to achieve a prolonged response in patients with multiple myeloma (PI19/00669)
Financing agency: Carlos III Health Institute
Start and end date: 01/01/2020 – 31/12/2022
- Phase II clinical trial on the use of a humanized CART directed against BCMA
Project title: Phase II clinical trial on the use of a humanized CART directed against BCMA (ARI0002h) in patients with multiple myeloma relapsed/refractory to proteasome inhibitors, immunomodulators and anti-CD38 antibodies (ICI19/00025)
Financing agency: Carlos III Health Institute
Start and end date: 01/01/2020 – 31/12/2023
- BCMA and SLAMF7 chimeric antigen receptors T-cells immunotherapy in multiple myeloma
Project title: BCMA and SLAMF7 chimeric antigen receptors T-cells immunotherapy in multiple myeloma (BITRECS)
Funding agency: European Union
Start and end date: 01/10/2019- 01/10/2021